Skip to main content

Ohio State Informaticists Unveil Database for Leukemia, Lymphoma Genes

NEW YORK, Dec. 22 (GenomeWeb News) - Bioinformaticists at Ohio State University have assembled a database of information on 246 genes which have been shown to be related to leukemia and lymphoma in humans and mice, the university announced today.


The database, HemoPDB, also contains data for 187 transcription factors and 604 experimentally verified binding sites, the university said.


HemoPDB was assembled by a team led by Ramana V. Davuluri, an assistant professor of bioinformatics in the human cancer genetics program and the department of molecular virology, immunology and medical genetics at Ohio State, and is described in the latest issue of Nucleic Acids Research. It is also available for public viewing here.


"The HemoPDB database pulls together information that was scattered over thousands of published research papers and dozens of web sites," Davuluri said in a statement."To our knowledge, it is the only database to compile the DNA sequences for the regulatory regions of genes involved in the development of blood cells and in cancers of the blood."


Davuluri and his colleagues plan to use HemoPDB as a framework to develop computational models for predicting which other genes are implicated in leukemia and lymphoma.



The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.